Nanostructured lipid carriers for enhanced in vitro and in vivo schistosomicidal activity of praziquantel: effect of charge

References

• Andrews P, Thomas H, Pohlke R, et al. Praziquantel. Med Res Rev. 1983;3:147–200.
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21:659–667.
   PubMed Web of Science ®Google Scholar
• Metwally A, Bennett J, Botros S, et al. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacol Res. 1995;31:53–59.
   PubMed Web of Science ®Google Scholar
• Maragos S, Archontaki H, Macheras P, et al. Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. AAPS PharmSciTech. 2009;10:1444–1451.
   PubMed Web of Science ®Google Scholar
• Neves BJ, Andrade CH, Cravo PV. Natural products as leads in schistosome drug discovery. Molecules. 2015;20:1872–1903.
   PubMed Web of Science ®Google Scholar
• Castro N, Jung H, Medina R, et al. Interaction between grapefruit juice and praziquantel in humans. AAC. 2002;46:1614–1616.
   Google Scholar
• Metwally A, Bennett JL, Botros S, et al. Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. Drug Res. 1995;45:516–518.
   Web of Science ®Google Scholar
• Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution of praziquantel by complexation with a-, b- and g-cyclodextrins. Int J Pharm. 1999;179:65–71.
   PubMed Web of Science ®Google Scholar
• El-Arini SK, Leuenberger H. Dissolution properties of praziquantel-PVP systems. Pharm Acta Helv. 1998;73:89–94.
   PubMedGoogle Scholar
• Wei J, Cheng F, Qun Q, et al. Epidemiological evaluations of the efficacy of slow-released praziquantel-medicated bars for dogs in the prevention and control of cystic echinococcosis in man and animals. Parasitol Int. 2005;54:231–236.
   PubMed Web of Science ®Google Scholar
• Cheng L, Lei L, Guo S. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. Int J Pharm. 2010;387:129–138.
   PubMed Web of Science ®Google Scholar
• De Souza AL, Andreani T, de Oliveira RN, et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463:31–37.
   PubMed Web of Science ®Google Scholar
• Mourão SC, Costa PI, Salgado HR, et al. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm. 2005;295:157–162.
   PubMed Web of Science ®Google Scholar
• Kolenyak-Santos F, Garnero C, de Oliveira RN, et al. Nanostructured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantel. J Nanosci Nanotechnol. 2015;15:761–772.
   PubMed Web of Science ®Google Scholar
• Ameeduzzafar Qumber M, Alruwaili NK, et al. BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov. 2021;16:85–98.
   Web of Science ®Google Scholar
• Garcês A, Amaral MH, Sousa Lobo JM, et al. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci. 2018;112:159–167.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346:124–132.
   PubMed Web of Science ®Google Scholar
• Li C, Li X, Li S, et al. Development and validation of a method for determination of encapsulation efficiency of CPT-11/DSPE-mPEG2000 nanoparticles. Med Chem. 2016;06:345–348.
   Google Scholar
• Smithers SR, Terry RJ. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 1965;55:695–700.
   PubMed Web of Science ®Google Scholar
• Fahmy ZH, El- Shennawy AM, El- Komy W, et al. Potential antiparasitic activity of pomegranate extracts against shistosomules and mature worms of Schistosoma mansoni: in vitro and in vivo study. Aust J Basic Appl Sci. 2009;3:4634–4643.
   Google Scholar
• Moraes JD, Nascimento C, Lopes PO, et al. Schistosoma mansoni: in vitro schistosomicidal activity of piplartine. Exp Parasitol. 2011;127:357–364.
   PubMed Web of Science ®Google Scholar
• Yousif F, Wassel G, Boulos L, et al. Contribution to in vitro screening of Egyptian plants for schistosomicidal activity. Pharm Biol. 2012;50:732–739.
   PubMed Web of Science ®Google Scholar
• Glauert AM. Fixation, dehydration and embedding of biological specimens: practical methods in electron microscopy. Amstersam (North-Holland): Elsevier Science; 1974.
   Google Scholar
• Ismail M, Metwally A, Farghaly A, et al. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214–218.
   PubMed Web of Science ®Google Scholar
• Zoghroban HS, El-Kowrany SI, Aboul Asaad IA, et al. Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation. Parasitol Res. 2019;118:219–234.
   PubMed Web of Science ®Google Scholar
• Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ. 1968;39:328–331.
   PubMedGoogle Scholar
• Von L. Host response to eggs of S. mansoni. I. Granuloma formation in the unsensitized laboratory mouse. Am J Pathol. 1962;41:711–731.
   PubMedGoogle Scholar
• Jacobs W, Bogers J, Deelder A, et al. Adult Schistosoma mansoni worms positively modulate soluble egg antigen-induced inflammatory hepatic granuloma formation in vivo. Stereological analysis and immunophenotyping of extracellular matrix proteins, adhesion molecules, and chemokines. Am J Pathol. 1997;150:2033–2045.
   PubMed Web of Science ®Google Scholar
• Claessens MM, van Oort BF, Leermakers FA, et al. Charged lipid vesicles: effects of salts on bending rigidity, stability, and size. Biophys J. 2004;87:3882–3893.
   PubMed Web of Science ®Google Scholar
• Eid RK, Ashour DS, Essa EA, et al. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carbohydr Polym. 2020;232:115826.
   PubMed Web of Science ®Google Scholar
• Yostawonkul J, Surassmo S, Iempridee T, et al. Surface modification of nanostructure lipid carrier (NLC) by oleoyl-quaternized-chitosan as a mucoadhesive nanocarrier. Colloids Surf B Biointerfaces. 2017;149:301–311.
   PubMed Web of Science ®Google Scholar
• Almeida H, Lobão P, Frigerio C, et al. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm Dev Technol. 2017;22:336–349.
   PubMed Web of Science ®Google Scholar
• Rabelo RS, Oliveira IF, da Silva VM, et al. Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: a physical stability study. Int J Biol Macromol. 2018;119:902–912.
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Campbell M, Finnin BC. Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes. Int J Pharm. 2005;305:90–104.
   PubMedGoogle Scholar
• Fang YP, Wu PC, Huang YB, et al. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine. 2012;7:4995–5005.
   PubMed Web of Science ®Google Scholar
• Jansook P, Pichayakorn W, Ritthidej GC. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations. Drug Dev Ind Pharm. 2018;44:1693–1700.
   PubMed Web of Science ®Google Scholar
• Takano R, Furumoto K, Shiraki K, et al. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res. 2008;25:2334–2344.
   PubMed Web of Science ®Google Scholar
• Ameeduzzafar Alruwaili NK, Imam SS, et al. Formulation of chitosan polymeric vesicles of ciprofloxacin for ocular delivery: box-behnken optimization, in vitro characterization, HET-CAM irritation, and antimicrobial assessment. AAPS PharmSciTech. 2020;21:167.
   PubMed Web of Science ®Google Scholar
• Pinto-Almeida A, Mendes T, de Oliveira RN, et al. Morphological characteristics of Schistosoma mansoni PZQ-resistant and -susceptible strains are different in presence of praziquantel. Front Microbiol. 2016;7:594.
   PubMed Web of Science ®Google Scholar
• Amara RO, Ramadan AA, El-Moslemany RM, et al. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int J Nanomedicine. 2018;13:4493–4505.
   PubMed Web of Science ®Google Scholar
• Rabia I, Nagy F, Aly E, et al. Effect of treatment with antifibrotic drugs in combination with PZQ in immunized Schistosoma mansoni infected murine model. J Am Sci. 2010;6:208–216.
   Google Scholar
• Cong Z, Shi Y, Peng X, et al. Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel. Drug Dev Ind Pharm. 2017;43:558–573.
   PubMed Web of Science ®Google Scholar
• Yang L, Geng Y, Li H, et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie. 2009;64:86–89.
   PubMed Web of Science ®Google Scholar
• Radwan A, El-Lakkany NM, William S, et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasit Vectors. 2019;12:304
   PubMed Web of Science ®Google Scholar
• Tawfeek GM, Baki MHA, Ibrahim AN, et al. Enhancement of the therapeutic efficacy of praziquantel in murine Schistosomiasis mansoni using silica nanocarrier. Parasitol Res. 2019;118:3519–3533.
   PubMed Web of Science ®Google Scholar